Abstract Library

#4658 The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,

#4656 Development of a 3D patient-derived extracellular matrix hydrogel model of small intestinal neuroendocrine tumour and mesenteric fibrosis

Introduction: The pathogenesis of mesenteric fibrosis in small intestinal neuroendocrine tumours (SI-NETs) is poorly understood, limiting development of effective treatments and biomarkers. A major barrier to research is the lack of disease models.

Conference:

Presenting Author:

Authors: Hodgetts H, Martins M, Luong T, Hall A, Webster A,

Keywords: small intestine, neuroendocrine, 3D model, hydrogel, fibrosis,

#4629 Identification of putative master regulators in pancreatic neuroendocrine tumours using gene expression data and network inference

Introduction: Pancreatic neuroendocrine tumours (pNETs) are a heterogenous group of pancreatic malignancies with a unique biology and pathophysiology. Tumour grade and extension are commonly used for prognostic determination. Current pathologic grading system needs regular updates to refine prognostic classification. Genomic screening may provide more objective classes and reflect tumour biology.

Conference:

Presenting Author: Jannin A

Authors: Jannin A, Elati M, Do Cao C, Figeac M, Leteurtre E,

Keywords: pancreatic neuroendocrine tumour, RNA-Seq, Master regulators, MEN1,

#4617 Analysis of new immunohistochemical biomarkers in a cohort of pancreatic NETs

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are rare diseases with a 10-year survival rate of only 40-50%. The ATRX, DAXX and ARX, PDX1 expressions in PanNETs were considered poor prognostic factors in some studies, but inconsistent in others.

Conference:

Presenting Author:

Authors: Ciobanu O, Martin S, Herlea V, Vasilescu F, Balaban D,

Keywords: Pancreatic neuroendocrine tumour, ATRX, DAXX, ARX, PDX1,

#4614 Rare diagnosis of intrapancreatic accessory spleen mimicking PanNET

Introduction: A 44-year-old woman with hypertension and an autoimmune thyroid disease. With a positive family history of pancreatic and oesophageal cancer. Referred to our clinic for an incidental finding of a tumour in the tail of the pancreas on abdominal ultrasound by a surgeon.

Conference:

Presenting Author: Uhrík P

Authors: Uhrík P, Nosakova L, Vojtko M, Bánovčin P,

Keywords: fine needle biopsy, accessory spleen, Neuroendocrine tumour,